1/13




FIG. 1




FIG. 2

2/13

Fatty acid composition of alkenylacyl, alkylacyl and diacyl subclasses in CPG in intestinal mucosa of animals fed control diet or treatment diets!

		Aukanyilacyi-CPG			Alkylacyl-CPG	5		Diacyl-CPG	
	Control	SM	8	Control	SM	99	Control	8	5
C 14:0	6.2 ± 1.6	8.1 ± 5.4	S.0 ± 1.3	54 ± 21	6.1 ± 2.5	> 0 + 79	20 + 80		3
C 14:1	1.9 ± 1.5	0.5 ± 0.3^{b}	0.4 ± 0.6 ^b	1.0 ± 0.7	0.3 + 0.4	50 T 50	7:0 H	F. 0.3	0.9 ± 0.2
C 16:0	33.7 ± 5.8	32.2 ± 8.6	32.3 ± 8.2	343 + 73	13 7 2 22	320 - 43		•	•
C 16:1(7)	1.4 ± 1.6	0.8 ± 0.5	91 + 11	24 - 70	1.0 # 5.50	0.50	21.0 ± 1.7	24.4 ± 2.2	24.3 ± 2.5"
C 18:0	25.5 + 3.7	03 T C:C	17 H 170	0.4 # 0.0	0.7 ± 0.6	0.4 ± 0.4	0.4 ± 0.0	0.3 ± 0.2	0.2 ± 0.1
0.18-170		C + 4 - 4	7.0 ± 0.7	25.8 ± 3.6	$17.6 \pm 5.7^{\circ}$	19.0 ± 4.6 ^{b†}	22.7 ± 1.1 ^b	24.8 ± 3.4°	27.7 ± 3.2 4
(2)	7 H 00	8.3 ± 4.3	5.9 ± 2.3	8.7 ± 3.1	7.7 ± 1.5	7.4 ± 1.3	11.6 ± 0.8	10.5 ± 0.8 ⁵	9.2 ± 1.19
(0)7:01 >	8.1 ± 2.6	3.2 ± 2.1	2.4 ± 1.6	5.3 ± 4.1	5.5 ± 1.8	5.5 ± 2.9	30.0 ± 1.6	26.6 ± 3.1 ^b	23.5 + 3.44
(0) (2)	0.5 ± 0.4	1.0 ± 1.2	0.7 ± 0.8	0.8 ± 0.6	0.7 ± 0.4	0.6 ± 0.7	0.1 ± 0.0	0.1 + 0.1	10 + 10
C18:3(3)	0.5 ± 0.6	0.3 ± 0.2	0.6 ± 0.6	0.5 ± 0.9	0.1 ± 0.2	0.4 ± 0.3	0.2 ± 0.0	0.1 + 0.0	01 + 10
C 20:0	1.2 ± 1.2	1.0 ± 0.4	1.9 ± 1.7	1.0 ± 0.2	0.8 ± 0.4	0.9 ± 0.6	0.3 ± 0.0	03 + 01	20 4
C 20:1	0.3 ± 0.4	0.6 ± 0.3	1.0 ± 0.7	0.4 ± 0.3	0.4 ± 0.4	0.6 ± 1.0	0.5 ± 0.1	100 + 00	3 6 H -
C 20:2	0.0 ± 0.1	0.1 ± 0.1	0.7 ± 1.1	0.1 ± 0.3	0.1 ± 0.2	26 + 30	10 + 00	00 H .	1.0 t
C 20:3(6)	0.3 ± 0.4	0.6 ± 0.7	0.4 ± 0.5	0.5 ± 0.6^{b}	13 + 13	\$10 T 00	0.4 + 0.1	i.i. 4 i.i. 4	0.7 ± 0.1
C 20:4(6)	1.8 ± 0.6 th	1.1 ± 0.5^{b}	3.1 ± 2.1	5.7 ± 3.7	95 + 48	0.2 + 6.1	0.4 # 0.1	0.4 ± 0.1	0.4 ± 0.1
C20:3(3)	0.3 ± 0.4	0.9 ± 0.8	0.7 ± 0.8	704 70	1 7 7		+ i i	8.8 ± 2.8	10.2 ± 1.5
C 20:5(3)	1.5 ± 0.9	70 + 90	22 - 22		# O H	0.3 ± 0.4	0.0 ≠ 0.0	0.0 ∓ 0.0	0.0 ≠ 0.0
C 22-0	970 + 50	0.0 H 0.0	0.2 ± 2.2	0.7 ± 0.6	0.8 ± 0.5	1.0 ± 0.5	0.3 ± 0.1	0.2 ± 0.1	0.3 ± 0.1
97.60	# C	C1 # 07	~17 + 77	1.3 ± 0.8	2.2 ± 1.3	1.8 ± 1.0	0.2 ± 0.0	0.2 ± 0.1	0.3 ± 0.2
(6)177	0:1 ± 1:0	1.5 ± 2.3	1.5 ± 1.6	0.1 ± 0.2^{b}	1.2 ± 1.0^{40}	1.7 ± 1.5*	0.2 ± 0.0	0.1 ± 0.0	0.2 + 0.0
(0)7:77	2.1 ± 1.1 =	1.5 ± 0.9°	4.0 ± 2.9"	0.0 ± 0.0 b	2.9 ± 2.6	1.2 ± 1.4 th	0.0 ± 0.0	0.1 + 0.2	101
C 22:4(6)	0.1 ± 0.3	0.0 ≠ 0.0	0.0 ± 0.0	0.4 ± 0.4	0.7 ± 0.9	0.6 ± 0.8	0.1 + 0.1	1 1 1 0	
C 24:0	2.4 ± 1.5	3.3 ± 1.5	3.2 ± 2.2	1.8 ± 1.04	1.8 ± 1.0	0.6 ± 0.8	00 + 10	70 7 10	20 C
C 22:6(3)	1.2 ± 1.1	0.9 ± 1.1	ъ	1.2 ± 1.0 ^b	2.7 ± 0.9°	42 ± 1.84	14 + 02	0.0 H	7.0 ± 7.0
C 24:1(9)	5.3 ± 2.9	7.5 ± 5.4	8.8 ± 3.6	40 ± 18	dero . or.	97.0.		+:- H	1.5 ± 0.2
SFA ³	27 + 7 9	704 ± 100	000 7 000	0'1 H 0'4	3.0 ± 0.7	1.8 ± 1.4°	0.1 ± 0.0	0.1 ± 0.1	0.2 ± 0.1
MITTA	101 + 40	10.4 ± 10.3	00.0	69.0 ± 10.6	61.8 ± 9.3	61.7 ± 7.8	45.2 ± 2.3 ^b	50.7 ± 5.5*	53.6 ± 5.8 ™
	13.1 # 4.0	19.4 ± 7.3	18.7 ± 2.6	14.6 ± 2.5	13.2 ± 1.9	12.4 ± 2.2	12.8 ± 0.9	11.5 ± 0.9 ^b	10.2 ± 1.1의
Mann	11.4 ± 3.6	10.2 ± 5.2	14.8 ± 4.9	FUCA 11.4 ± 3.6 10.2 ± 5.2 14.8 ± 4.9 15.8 ± 8.9 25.0 ± 7.6 25.9 ± 6.6 42.0 ± 1.7 37.7 ± 5.7 ± 3.62 ± 4.8 17 11.7 37.7 ± 5.7 18.2 ± 4.8 11.7 11.7 11.7 11.7 11.7 11.7 11.7 11	25.0 ± 7.6 *	25.9 ± 6.6	42.0 ± 1.7*	37.7 ± 5.7^{40}	36.2 + 4.8 ^b

FIG. 3

Fatty acid composition of alkenylacyl, alkylacyl and diacyl subclasses in EPG in intestinal mucosa of animals fed control diet or treatment diets¹

		Alkenylacyl-EPG			Alicylacyl-EPG			Diacyl-EPG	
	Control	SM	99	Control	SM	8	Control	WS	9
C14:0	3.9 ± 1.3	3.1 ± 1.1	3.1 ± 1.2	4.4 ± 1.5	3.0 ± 1.9	2.5 ± 1.5	0.7 ± 0.4	10 + 01	20 + 50
C 14:1	0.7 ± 0.3	0.9 ± 1.0	0.5 ± 0.4	0.7 ± 0.6	0.2 ± 0.2^{5}	0.2 ± 0.1	; i		4 ·
C 16:0	19.0 ± 3.6	15.4 ± 1.7 ^b	14.2 ± 2.3 th	18.7 ± 5.4	12.7 ± 3.2 ^b	11.4 ± 1.9 ^{bt}	9.8 ± 2.5	81 + 58	1 1 0
C 16:1(7)	2.1 ± 1.3	2.5 ± 0.7	2.3 ± 0.6	0.6 ± 0.5	0.3 ± 0.2	0.3 ± 0.3	10 + 10	9:1 + 10	9.1 # 1.0
C 18:0	17.6 ± 4.7	14.4 ± 4.1 tb	11.6 ± 2.7^{b}	14.8 ± 3.2	11.2 ± 4.0 ^b	9.8 ± 2.1 b	46.9 ± 8.6	43.5 ± 7.4	426 + 43
C 18:1(9)	9.0 ± 2.0	8.2 ± 1.2	7.3 ± 0.9	12.0 ± 3.1	11.6 ± 1.9	9.2 ± 1.3	12.2 ± 2.9	13.1 ± 2.1	12.8 ± 1.5
C 18:2(0)	4.0 ± 1.3	4.6 ± 0.5	4.1 ± 0.7	5.4 ± 1.0	6.4 ± 0.6	5.6 ± 0.8	11.8 ± 3.3	14.7 ± 3.0	142 + 18
C 18:3(6)	0.6 ± 0.3	0.6 ± 0.1	0.3 ± 0.1 b	0.5 ± 0.4	0.5 ± 0.3	0.4 ± 0.2	0.2 ± 0.1	0.1 ± 0.1	0.2 ± 0.0
C 18:3(3)	2.2 ± 1.2	2.1 ± 0.9	2.1 ± 1.0	0.5 ± 0.3	0.6 ± 0.3	0.6 ± 0.2	0.3 ± 0.5	0.2 ± 0.1	0.1 # 0.0
C 20:0	0.6 ± 0.2	0.5 ± 0.2	0.5 ± 0.2	1.6 ± 1.2	1.1 ± 0.2	1.1 ± 0.1	0.5 ± 0.2	0.5 ± 0.1	0.3 ± 0.3
C 20:1	1.0 ± 0.8	1.0 ± 0.2	0.8 ± 0.1	2.1 ± 1.2	2.1 ± 0.4	2.1 ± 0.5	0.3 ± 0.1	0.2 ± 0.1	0.2 ± 0.1
C 20:2	1.2 ± 1.4	0.5 ± 0.7	1.1 ± 0.9	0.4 ± 0.3	0.5 ± 0.3	0.7 ± 0.3	0.4 ± 0.6	0.2 ± 0.1	0.1 ± 0.0
C 20:3(6)	0.8 ± 0.6	0.9 ± 0.3	0.9 ± 0.2	1.0 ± 0.5	1.2 ± 0.6	1.6 ± 0.5	0.4 ± 0.2	0.5 ± 0.2	0.4 ± 0.3
C 20:4(6)	16.9 ± 5.7	21.3 ± 3.9	23.1 ± 4.9	13.5 ± 6.1 b	21.9 ± 4.6 tb	25.1 ± 2.6	11.5 ± 3.6 ^b	14.0 ± 3.5 tb	15.7 ± 2.6
C 20:3(3)	0.5 ± 0.2^{4}	0.3 ± 0.2 tb	. 0.2 ± 0.1 ^b	0.4 ± 0.2	0.4 ± 0.2	0.3 ± 0.2	0.1 ± 0.1	0.1 ± 0.1	0.0 # 0.0
C 20:5(3)	0.6 ± 0.3	0.4 ± 0.3	0.5 ± 0.2	0.8 ± 0.3	0.7 ± 0.4	0.6 ± 0.3	0.3 ± 0.1	03 ± 0.2	0.2 ± 0.2
C 22:0	1.3 ± 0.7	1.0 ± 0.6	0.9 ± 0.2	0.7 ± 0.6	0.7 ± 0.5	1.2 ± 0.9	0.5 ± 0.2	0.3 ± 0.1	0.4 ± 0.2
C 22:1(9)	0.4 ± 0.4	0.4 ± 0.4	0.8 ± 0.8	0.5 ± 0.5	1.1 ± 0.9	1.0 ± 1.1	0.3 ± 0.4	0.2 ± 0.1	0.2 ± 0.1
C 22:2(6)	1.2 ± 1.5	0.5 ± 0.2	0.7 ± 0.3	1.5 ± 0.9	1.6 ± 1.1	1.2 ± 0.5	0.4 ± 0.3	0.0 ± 0.0	0.0 ± 0.16
C 22:4(6)	4.9 ± 2.8^{b}	7.8 ± 1.6^{4}	9.9 ± 2.1 4	5.8 ± 2.3 ^b	8.3 ± 2.9 tb	10.9 ± 2.2 4	0.3 ± 0.2	0.4 ± 0.2	0.6 ± 0.5
C 24:0	23 ± 1.9	1.4 ± 0.7	0.9 ± 0.5	1.4 ± 0.4	1.6 ± 0.7	0.7 ± 0.5 ^b	#	0.2 ± 0.1	0.3 ± 0.2
C 22:6(3)	7.4 ± 2.6°	10.1 ± 0.9 ^b	12.7 ± 1.84	6.3 ± 1.9 ^b	92 ± 23	112 ± 124	2.0 ± 1.0	23 ± 1.1	2.7 ± 0.5
C 24:1(9)	2.5 ± 1.4	23 ± 1.5	1.5 ± 1.1	1.3 ± 0.7	2.6 ± 1.6	24 ± 23	0.6 ± 0.5	0.3 ± 0.1	43
SFA ²	44.7 ± 9.7°	35.7 ± 5.9^{b}	31.2 ± 5.5 ^{b†}	41.6 ± 9.8ª	30.2 ± 7.1 b	26.7 ± 4.4 ^{tt}	58.6 ± 9.8	53.3 ± 8.8	50.4 ± 4.9
MUFA	15.7 ± 4.2	15.2 ± 2.5	13.2 ± 2.1	17.2 ± 3.0	17.9 ± 2.8	15.2 ± 2.4	13.6 ± 2.8	13.9 ± 2.1	13.4 ± 1.1
PUFA	39.4 ± 11.3 b	49.1 ± 5.4*	PUFA 39.4 ± 11.3 b 49.1 ± 5.4	41.2 ± 11.5°	51.9 ± 9.4	58.1 ± 4.2 ^{4†}	27.8 ± 7.4 ^b	32.8 ± 7.04b	36.2 ± 4.2

FIG. 4

WO 2004/087173 PCT/CA2004/000375




FIG. 5




FIG. 6

5/13




FIG. 7

(A)

(B)





FIG. 8

WO 2004/087173 PCT/CA2004/000375










FIG. 9


7/13




8/13



9/13










FIG. 12










FIG. 13

WO 2004/087173 PCT/CA2004/000375

10/13









FIG. 14

11/13


Composition of GM3 and GD3 in microdomains



Diet treatment

FIG. 15

Content of PAF and DG in microdomains



Diet treatment

Content is presented by ug/mg protein

FIG. 16

12/13

21-24 kD, a marker protein of caveolae 20 30,30 20 30 20 30 |20ug _| Caveolin-1 Caveolin :

13/13

Diet group/Statistical P value	Control	SM	99	Ъ
NANA (mg/DL)	1.02 ± 0.14^{b}	1.02 ± 0.10^{b}	1.34 ± 0.20°	0.003
Phosphorus (mg/DL)	6.83 ± 0.71	6.92 ± 0.34	6.81 ± 0.22	ı
Cholesterol (mg/DL)	111.3±11.4ªb	117.8 ± 8.5ª	105.4 ± 4.2 ^b	0.03
Triglyceride (mg/DL)	94.7 ± 27.0^{ab}	$107.1\pm18.5^{\rm a}$	76.8 ± 10.5^{b}	0.02
NANA/P ratio (mg/mg)	$0.15\pm0.02^{\rm b}$	0.15 ± 0.02^{b}	0.20 ± 0.03^{a}	0.006
Cholesterol/NANA ratio (mg/mg)	110.1 ± 19.1^{a}	115.5 ± 14.1^{a}	80.4 ± 11.2^{b}	0.002
Cholesterol/P ratio (mg/mg)	16.26 ± 1.23ªb	16.97 ± 1.05^{a}	15.34 ± 0.72^{b}	90.0

FIG. 18

SUBSTITUTE SHEET (RULE 26)